Manuel Smithers's questions to Moderna Inc (MRNA) leadership • Q3 2024
Question
On behalf of Emmanuel Smithers, a question was asked about the expected speed of the market's transition to a flu/COVID combo vaccine and for an update on COVID-related litigation, particularly the recent GSK lawsuit.
Answer
President Stephen Hoge stated that a market transition to the combo vaccine is not expected in 2025 due to the timing of flu contracting, but the company is bullish on the long-term opportunity for 2026 and beyond. CEO Stéphane Bancel declined to comment on the merits of the GSK case but noted the company is prepared to defend itself.